News - Hikma
WEBHikma Pharmaceuticals reaffirms commitment to expanding access to overdose-reversal medicine naloxone at White House mee... Hikma opens new UK office to support NHS supply, strengthening European presence
Hikma has strong start to 2024, with continued momentum across …
WEBApr 25, 2024 · Hikma is a multinational pharmaceutical group with three business segments: Injectables, Branded and Generics. It reports strong growth and momentum in the first quarter of 2024 and reiterates its full year guidance.
Hikma Pharmaceuticals PLC Just Beat EPS By 12%: Here's What …
WEBAug 11, 2024 · Hikma Pharmaceuticals beat earnings and revenues in its latest results, but analysts expect slow growth and no change in valuation. See the details, comparisons and risks of the company's...
Hikma acquires Xellia’s differentiated portfolio and enhances ...
WEBJun 17, 2024 · Hikma Pharmaceuticals PLC announces the acquisition of parts of Xellia Pharmaceuticals' US finished dosage form business and assets, including a commercial portfolio, pipeline, manufacturing facility and R&D center. The transaction will enhance Hikma's injectables pipeline, capacity and capabilities in the US and global markets.
Hikma strengthens US Injectables business through acquisition of …
WEBSep 27, 2021 · Hikma, a global pharmaceutical company, announces the acquisition of Custopharm, a US-based generic sterile injectables company, for $375 million. The deal adds 13 approved products and a...
Hikma completes Xellia acquisition | Drug Store News
WEB9/12/2024. Supports the long-term growth of Hikma’s Injectables business. Diversifies and enriches Hikma’s U.S. injectables portfolio and pipeline. Expands Hikma’s high-quality manufacturing ...
Hikma completes acquisition of Custopharm - PR Newswire
WEBApr 21, 2022 · As previously announced on 27 September 2021, Hikma has acquired Custopharm for an initial cash consideration of $375 million on a debt and cash-free basis, with a further $50 million in...
Hikma announces US FDA approval of KLOXXADOTM (naloxone hydrochloride ...
WEBApr 30, 2021 · Hikma announces the approval of KLOXXADOTM, a nasal spray for reversing opioid overdoses, by the US Food and Drug Administration. KLOXXADOTM contains twice as much naloxone per spray as Narcan ®...
Hikma Pharmaceuticals rises Thursday, outperforms market
WEB3 days ago · Shares of Hikma Pharmaceuticals PLC HIK rallied 2.61% to £19.64 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0. ...
Hikma Pharmaceuticals PLC (HIK.L) - Yahoo Finance
WEBGet the latest Hikma Pharmaceuticals PLC (HIK.L) stock news and headlines to help you in your trading and investing decisions.
Skip to content